Chantal Farra

Chantal Farra

Auto-generated profile, based on publicly available information

Chantal Farra

Department of Pathology and Laboratory Medicine, American University of Beirut Medical Center, Beirut, Lebanon

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 January 2019 in Hereditary Cancer in Clinical Practice
Verified
Journal Article
Open access
PDF file
CFChantal Farra
Chantal Farra
CDChristelle Dagher
Christelle Dagher
RBRebecca Badra
Rebecca Badra
MHMiza Salim Hammoud
Miza Salim Hammoud
RARaafat Alameddine
Raafat Alameddine
DMDeborah Mukherji
Deborah Mukherji
Previous studies have suggested that the prevalence of BRCA1 and 2 mutations in the Lebanese population is low despite the observation that the median age of breast cancer diagnosis is significantly lower than European and North American populations. We aimed at reviewing the rates and patterns of BRCA1/2 mutations found in individuals referred to the medical genetics unit at the American University of Beirut. We also evaluated the performance of clinical prediction tools. We retrospectively reviewed the cases of all individuals undergoing BRCA mutation testing from April 2011 to May 2016. To put our findings in to context, we conducted a literature review of the most recently published data from the region. Two-hundred eighty one individuals were referred for testing. The prevalence of mutated BRCA1 or 2 genes were 6 and 1.4% respectively. Three mutations accounted for 54% of the pathogenic mutations found. The BRCA1 c.131G > T mutation was found among 5/17 (29%) unrelated subjects with BRCA1 mutation and is unique to the Lebanese and Palestinian populations. For patients tested between 2014 and 2016, all patients positive for mutations fit the NCCN guidelines for BRCA mutation screening. The Manchester Score failed to predict pathogenic mutations. The BRCA1 c.131G > T mutation can be considered a founder mutation in the Lebanese population detected among 5/17 (29%) of individuals diagnosed with a mutation in BRCA1 and among 7/269 families in this cohort. On review of recently published data regarding the landscape of BRCA mutations in the Middle East and North Africa, each region appears to have a unique spectrum of mutations.

18 June 2014 in Ophthalmic Genetics
Verified
Journal Article
Closed access
PDF file
CAChristiane Al-Haddad
Christiane Al-Haddad
MAMarwan Abdulaal
Marwan Abdulaal
RBRebecca Badra
Rebecca Badra
ABAnita Barikian
Anita Barikian
BNBahaa Noureddine
Bahaa Noureddine
CFChantal Farra
Chantal Farra
Background: The incidence of primary congenital glaucoma (PCG) varies among geographic regions and ethnic groups. The frequency of PCG in Lebanon and identification of disease-causing mutations have not been studied previously. Purpose: To investigate the role of Cytochrome P1B1 (CYP1B1) gene and Myocillin (MYOC) gene mutations in PCG in the Lebanese population and study possible genotype/phenotype correlations. Methods: Patients with unilateral or bilateral PCG diagnosed at the American University of Beirut Medical Center and their first-degree relatives (parents and siblings) were screened for CYP1B1 and MYOC mutations. Demographic and phenotypic characteristics were recorded. Phenotypic characteristics pertaining to disease severity and outcomes were compared. Results: Eighteen Lebanese families (66 subjects) with at least one member affected with PCG were included in this study. Mutations in the CYP1B1 gene were detected in 6 families (33%). Five previously described mutations (p.R444Q; p.E229K; p.R469W; p.G61E; p.M1T) and one new single nucleotide deletion were identified (1793delC). Patients in whom CYP1B1 mutations were detected tended to have a more severe phenotype as evidenced by earlier age at diagnosis, higher rate of bilateral disease, and higher number of glaucoma surgeries than those in whom no CYP1B1 mutations were present. MYOC gene mutations were not detected in any patients. Conclusion: The rate of CYP1B1 mutations in Lebanese patients with PCG is lower than that reported in other Arab and Middle Eastern populations and suggests other genes are responsible for PCG in the remainder.

25 July 2014 in Journal of the European Academy of Dermatology and Venereology
Verified
Journal Article
Closed access
PDF file
DSD. Saadeh
D. Saadeh
MKM. Kurban
M. Kurban
SGS. Ghosn
S. Ghosn
WBW. Btadini
W. Btadini
Georges NemerGeorges Nemer
Georges Nemer
CFC. Farra
C. Farra

24 September 2012 in International Journal of Hyperthermia
Verified
Journal Article
Closed access
JAJohnny Awwad
Johnny Awwad
GGGhina Ghazeeri
Ghina Ghazeeri
TTThomas Toth
Thomas Toth
AHAntoine Hannoun
Antoine Hannoun
MAMichel Abou Abdallah
Michel Abou Abdallah
CFChantal Farra
Chantal Farra
Purpose: This study aims to evaluate the effects of fever on follicular development in women undergoing controlled ovarian stimulation during in vitro fertilisation (IVF) and intracytoplasmic sperm injection (ICSI) cycles. Materials and methods: This was a retrospective observational self-controlled study at a tertiary-care fertility centre. Six gonadotropin stimulation cycles characterised by poor ovarian response in which women reported the occurrence of a febrile illness, were considered for evaluation. Fever-exposed cycles were compared to the next stimulation cycle in the same women. Primary outcome measures were final number of pre-ovulatory follicles (≥ 16 mm) and final peak serum estradiol levels (pg/mL). Other outcome measures were final number of medium-sized follicles (12–15 mm), final mean estradiol serum level per follicle ≥ 12 mm (pg/mL), total days of stimulation and total gonadotropin ampoules utilised. Results: Fever-exposed cycles were associated with significantly lower number of pre-ovulatory follicles (0.7 ± 0.8), significantly higher number of medium-size follicles (21.0 ± 4.5), and significantly reduced serum estradiol per follicle ≥12 mm (50.7 ± 11.7 pg/mL). They also required a significantly longer duration of ovarian stimulation (15.7 ± 3.3 days) and a significantly increased number of gonadotropin ampoules (47.2 ± 10.9). Four women had polycystic ovary syndrome and one hypothalamic hypogonadism. Conclusion: This preliminary report suggests a possible negative effect of fever on follicular development and ovarian estradiol production in some women undergoing controlled ovarian stimulation.

1 November 2012 in Acta Obstetricia et Gynecologica Scandinavica
Verified
Journal Article
Closed access
PDF file
JAJohnny T. Awwad
Johnny T. Awwad
GGGhina S. Ghazeeri
Ghina S. Ghazeeri
AHAntoine Hannoun
Antoine Hannoun
KIKeith Isaacson
Keith Isaacson
MAMichel Abou‐Abdallah
Michel Abou‐Abdallah
CFChantal G. Farra
Chantal G. Farra